MESSAGE FROM THE CEO
InnFocus is working to provide a safe, effective, sustainable and easy to perform alternative for the surgical treatment of glaucoma. Our lead product—the InnFocus MicroShunt® glaucoma drainage implant-- is showing promising clinical results.
The company will be seeking FDA approval for the InnFocus MicroShunt System, as the first minimally invasive stand-alone procedure for mild, moderate, and severe stage open angle glaucoma, which lowers and sustains IOP under 15 mm Hg, with the potential to eliminate eye drop medications in most patients. Unlike many MIGS (micro-invasive glaucoma surgery) technologies, the InnFocus MicroShunt does not require simultaneous removal of the cataract.
The final phase of the FDA randomized clinical study comparing the InnFocus MicroShunt System to trabeculectomy is underway.
In clinical trials outside the United States, we are achieving a mean post-operative Intraocular Pressure (IOP) below 15mm Hg, which ophthalmologists believe reduces a major risk factor for optic nerve damage and reduction of vision. Also, over 70% of the patients have eliminated their use of eye drop medication at 3 years after their procedure. Therefore, the effect appears to be uniquely durable.
Glaucoma affects over 78 million people worldwide. The disease is a serious health care problem that is not always easy to diagnose and, often, is difficult to treat. Our InnFocus MicroShunt® addresses the largest patient segment in glaucoma.
The Company’s revolutionary SIBS material is ultra-stable, will not degrade and has a 13-year proven history in drug eluting coronary stents. Our scientists have used it to develop an innovative minute ophthalmic device.
Our team is working hard every day to advance this technology. We invite you to learn more about our company on our website.
President & Chief Executive Officer